AGEN - AGENUS INC

3.24
-0.150   -4.630%

Share volume: 257,048
Last Updated: 03-30-2026
Pharmaceutical Products/Biological Products, Except Diagnostic Substances: -0.03%

PREVIOUS CLOSE
CHG
CHG%
$3.39
-0.15
-0.04%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
43%
Profitability 35%
Dept financing 43%
Liquidity 10%
Performance 60%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
-5.81%
1 Month
1.89%
3 Months
3.18%
6 Months
-16.92%
1 Year
115.28%
2 Year
451.49%
Key data
Stock price
$3.24
P/E Ratio 
N/A
DAY RANGE
$3.22 - $3.39
EPS 
-$0.39
52 WEEK RANGE
$1.38 - $7.34
52 WEEK CHANGE
$102.50
MARKET CAP 
0.000
YIELD 
N/A
SHARES OUTSTANDING 
38.398 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
05-06-2025
BETA 
5.79
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$294,976
AVERAGE 30 VOLUME 
$529,026
Company detail
CEO: Garo H. Armen
Region: US
Website: agenusbio.com
Employees: 440
IPO year: 2000
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Biological Products, Except Diagnostic Substances
Sector: Manufacturing

Agenus Inc. discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It also develops Balstilimab, an anti-PD-1 antagonist that has completed Phase II clinical trial to treat second line cervical cancer.

Recent news